Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2007
10/23/2007US7285642 Composition and method for modulating dendritic cell-T cell interaction
10/23/2007US7285574 Methods for treating neural cell swelling
10/23/2007US7285552 For prevention and/or treatment for HIV infection or AIDS induced by the infection
10/23/2007US7285551 For use as therapeutic agent and prophylactic agent for hepatitis C
10/23/2007US7285535 Administering TIRAP to block Toll/Interleukin-1 Receptor Adaptor Protein signaling in a cell; for treatment of inflammation and inducing or affecting immune response.
10/23/2007US7285525 Suppression of immune response via inhibition of cathepsin S
10/23/2007US7285517 Warming and nonirritating lubricant compositions and method of comparing irritation
10/23/2007US7285382 Compositions and methods for treatment of cancer
10/23/2007US7285292 Adding an EDTA/NaOH mixture to acontainer and subsequently adding at least one metal compound; adding Na2SeO3 to the container to obtain the trace element solution; improve the trace mineral status of an animal
10/23/2007US7285279 Method of treating malignancies and viral infections and improving immune function with a dietary supplement
10/23/2007US7285273 Administering an immunogenically effective amount of TH epitope-containing IL5 polypeptide wherein TH epitope-containing IL5 polypeptide differs from the animal's autologous IL5 polypeptide in that the TH epitope-containing IL5 polypeptide comprises at least one foreign TH epitope
10/23/2007CA2380052C Nicotine receptor agonists in stem cell and progenitor cell recruitment
10/23/2007CA2244209C Improved concentrated injection and infusion solutions for intravenous administration
10/18/2007WO2007117038A1 Prophylactic/therapeutic agent for cancer
10/18/2007WO2007116962A1 Muscle regeneration promoter
10/18/2007WO2007116925A1 hCL-K1 POLYPEPTIDE HAVING COLLECTIN ACTIVITY
10/18/2007WO2007116632A1 Microparticles, microparticle dispersion and method and apparatus for producing the same
10/18/2007WO2007116458A1 Therapeutic agent for neurodegenerative disease
10/18/2007WO2007116147A1 Healing composition
10/18/2007WO2007116029A2 Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
10/18/2007WO2007115620A2 Novel cyclobutyl compounds as kinase inhibitors
10/18/2007WO2003003809A3 Methods of using electron active compounds for managing conditions afflicting mammals
10/18/2007US20070244160 6-11 Bicyclic Ketolide Derivatives
10/18/2007US20070244124 For therapy of multi-drug resistant disease; combination therapy; anticarcinogenic agent; leukemia; hydrochloride salt; obtained with copper radiation source
10/18/2007US20070244063 Inducing angiogenesis comprising contacting endothelial cells expressing Bv8 receptor with a polypeptide comprising the amino acid sequence of SEQ ID NO:2; using Bv8 polypeptides to induce endothelial cell proliferation and to enhance endothelial cell survival; screening for Bv8 modulators
10/18/2007US20070244053 Use of a CD40:CD154 binding interruptor to prevent counter-adaptive immune responses, particularly graft rejection
10/18/2007US20070244030 Method for Assessing Cancerous State
10/18/2007US20070243311 Weight management system for obese animals
10/18/2007US20070243270 prevent skin damage caused by ultraviolet radiation by administering a oral dosage of alpha-lipoic acid, n-acetyl cysteine, green tea extract, turmeric extract, and quercetin, and applying s topical dosage form comprising plant extracts of berry, bitter orange peel, lemon, cucumber and herbs
10/18/2007US20070243251 Dosage Forms Containing A PPI, NSAID, and Buffer
10/18/2007US20070243160 Remedies for nerve damages
10/18/2007US20070243158 Skin care compositions and treatments
10/18/2007DE102006016991A1 Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen The use of kappa opioid receptor antagonists for the treatment of dissociative disorders
10/18/2007CA2648644A1 Muscle regeneration promoter
10/18/2007CA2647803A1 Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
10/18/2007CA2647690A1 Novel cyclobutyl compounds as kinase inhibitors
10/17/2007EP1845106A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
10/17/2007EP1844794A1 Silicon implants comprising a radionucleotide and/or a cytotoxic drug and their use in cancer treatment
10/17/2007EP1844792A1 Therapeutic agent for constipation
10/17/2007EP1844787A1 Drugs for nerve cell regeneration
10/17/2007EP1844774A2 A pharmaceutical composition for angiotensin II-mediated diseases
10/17/2007EP1844734A2 Combination drug therapy for reducing scar tissue formation
10/17/2007EP1844069A1 Molecules and chimeric molecules thereof
10/17/2007EP1843754A1 New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance
10/17/2007EP1608349B1 Oral delivery system comprising an antibacterial and an anti-inflammatory agent
10/17/2007EP1546216B1 Methods of drug delivery using sulphated chitinous polymers
10/17/2007EP1434991B1 New potent, selective and non toxic c-kit inhibitors
10/17/2007EP1372638A4 Functional role for cannabinoids in autonomic stability during sleep
10/17/2007EP1347745A4 Dietary composition containing conjugated linoleic acid and calcium for improved health
10/17/2007EP1341769B1 Bacterial gyrase inhibitors and uses thereof
10/17/2007EP1284724A4 Method of preparing alkylated salicylamides via a dicarboxylate intermediate
10/17/2007EP1267848B1 Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer
10/17/2007EP1153034B1 Growth hormone secretagogues
10/17/2007EP1144006B1 CCR5 Antibody PA14
10/17/2007EP1141728B1 Kidney disease detection and treatment
10/17/2007EP1092018B1 Kv6.2, A VOLTAGE-GATED POTASSIUM CHANNEL SUBUNIT
10/17/2007EP1059882B1 Integrated tissue poration, fluid harvesting and analysis device
10/17/2007EP0993613B8 Method for recognizing and determining gnrh receptors and the use of gnrh agonists and gnrh antagonists and other gnrh receptor ligands for the treatment with gnrh receptors of tumours originating in the brain and/or nervous system and/or meninges and/or of kaposi sarcoma
10/17/2007CN101056855A Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
10/17/2007CN101056656A Reducing ER stress in the treatment of obesity and diabetes
10/17/2007CN101056628A Ester derivatives and medicinal use thereof
10/17/2007CN101054419A Vectors with modified protease-dependent tropism
10/17/2007CN101053662A Nonsteroidal antiinflammatories with nitric oxide donors and its preparation method
10/17/2007CN101053659A Carried nitrosoureas medicine and alkaloids medicine for anti-cancer composition
10/17/2007CN101053573A Compositions and methods based on VEGF antisense oligonucleotides
10/17/2007CN101053561A Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis
10/17/2007CN101053551A Carried nitrosoureas drug and alkylating agent for anti-cancer composition
10/17/2007CN100343268C Beta -2'-or 3'-halonucleosides
10/17/2007CN100343252C Novel imidazopyridine compounds with therapeutic effect
10/17/2007CN100343229C 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of PPAR-alpha
10/17/2007CN100343223C Ester compound of thymol and/or carvacrol, preparing method and its medicinal active composition
10/17/2007CN100342913C Aspirin-containing transdermal pharmaceutical composition for the treatment of calcification
10/17/2007CN100342912C Sustained release composition for oral administration of drugs
10/17/2007CN100342860C Actacid composition
10/17/2007CN100342853C Therapeutic treatment
10/16/2007US7282620 Animal does not develop anaphylaxis, a type I allergy, and specifically induces Arthus reaction, a type III allergy
10/16/2007US7282585 Salt and crystalline forms of (2R)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline
10/16/2007US7282518 Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
10/16/2007US7282510 neurotrophic N-glyoxyl-prolyl ester compounds e.g. (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidine carboxylic acid; non-immunosuppressive; side effect reduction; neurodegenerative diseases
10/16/2007US7282501 Drugs for treatment of Syndrome X, diabetes, hypoglycemic agents, antilipemic agents, arteriosclerosis and cardiovascular agents
10/16/2007US7282484 Oral administration of an amino acid with a N-terminal blocking group and a N-(2-boric pyrrolyl) group attached to the carboxyl group; anticarcinogenic, antiproliferative, antimetastasis agents for lung, kidney, pancreatic, breast, and colorectal cancers; angiogenesis inhibition
10/16/2007US7282479 or a vector into which a cytokine gene is integrated so that cytokine can be expressed in the malignant tumor cell; particle surfaces may be bound to an antibody which selectively binds to malignant tumor cells.
10/16/2007US7282470 Neutralizes the adverse health effects of both chemical and biological compounds, especially chemical and biological warfare agents, and toxic industrial chemicals; includes solubilizers and oxididative detoxifiers
10/16/2007US7282344 Also mutated GABAA receptor subunits, polynucleotide sequences encoding mutated subunits, expression vectors comprising the mutated subunits, host cells capable of expressing the mutated subunits, drug screening methods, and chemical substances identified by the method; high throughput drug screening
10/16/2007US7282206 Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
10/16/2007CA2248087C Improved vision through photodynamic therapy of the eye
10/16/2007CA2214026C Pharmaceutical compositions comprising monoamine oxidase b inhibitors
10/11/2007WO2007114262A1 Casein nanoparticle
10/11/2007WO2007114239A1 ANTI-CANCER AGENT COMPRISING DGKα INHIBITOR
10/11/2007WO2007113748A1 Oral formulation with beneficial cardiovascular effects, comprising berberine
10/11/2007WO2007113243A2 Use of pde 5 inhibitors for the treatment of overactive bladder
10/11/2007WO2007094495A3 Novel anticancer cathepsin preparation and anticancer agent for combination therapy against cancer using the same
10/11/2007WO2007088050A3 Method of treatment for muscular dystrophy
10/11/2007WO2007085567A3 Synergistic compositions for treating hiv
10/11/2007WO2007071313A3 Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
10/11/2007WO2007070632A3 Abuse resistant transmucosal drug delivery device
10/11/2007WO2007057714A3 Pharmaceutical compositions comprising methotrexate
10/11/2007WO2007030580A3 Neuroprotectants
10/11/2007US20070238862 natural ligand for the orphan G-Protein Coupled Receptor (GPCR) ChemerinR and uses thereof in diagnosis and immuno therapy of a disease; monoclonal antibody; chemiattractant proteins; useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of GPCR signaling
10/11/2007US20070238791 Methods and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using RXR modulators
1 ... 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 ... 1151